01.12.2021 | Tracker

Product Launch Tracker: HCPs welcome approvals for MSD’s Keytruda and Takeda’s Livtencity

By Paul Cranston and Tomi Shobande

Every month, CREATION.co’s tracking updates bring you the latest insights from the conversation of healthcare professionals (HCPs) across the globe discussing product launches. Discover which new drug approvals HCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.


Throughout November 2021 we tracked the global conversations of 3,037 HCPs who posted 4,615 English-language Twitter posts about the launches and approvals of new products.

Image of a graph showing HCP mentions of product launches on twitter in November 2021

Over the course of November, the FDA approval of Merck MSD’s Keytruda (pembrolizumab) for the adjuvant treatment of patients with renal cell carcinoma (RCC) was the key talking point among HCPs. The treatment is to be used in patients at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. HCPs were pleased with the news as they saw it as a step in the right direction and a game-changer for the kidney cancer therapy area.

The FDA also approved Takeda’s Livtencity (maribavir) as the first and only treatment for people aged 12 and older with post-transplant cytomegalovirus (CMV) that is refractory, with or without genotypic resistance, to conventional antiviral therapies. HCPs shared their excitement for the approval of Livtencity (maribavir) and look forward to more treatment options being available.

HCPs also welcomed the news that the European Medicines Agency (EMA) recommended Pfizer’s COVID-19 Vaccine for approval in children aged 5-11. This age group would receive a lower dose of the Comirnaty vaccine than used in people aged 12 and older.

The three most shared links from HCPs discussing product launches in November were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.


  • Using CREATION Pinpoint®, the English-language Twitter conversations of HCPs globally discussing new pharmaceutical product launches and drug approvals between 1 November and 30 November 2021 were analysed in order to discover which new product launches HCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by HCPs in their Twitter conversations.
  • Between 1 November and 30 November 2021, there were 4,615 HCP mentions of new pharmaceutical product launches and drug approvals from 3,037 unique HCP authors from around the world. 

View the latest product launch and archived trackers here

View all articles >

Meet the Authors

Paul Cranston

Paul analyses the online conversations of HCPs to provide insights for pharmaceutical companies about what HCPs think. With a background in international development, he is passionate about using data to reveal the unmet needs in healthcare communities.

In his free time, Paul can often be found either writing songs on his guitar or kicking a ball around on a football field.

Tomi Shobande

Tomi is passionate about building relationships with clients and helping them attain their business goals and objectives. With a background in law, international development and human rights, she is keen on bringing about a positive difference around healthcare inequities and shaping health outcomes for all groups.

Tomi enjoys spending good quality time with friends and family. She also is passionate about travel and learning different cultures and histories along the way.

Suggested next

15.11.2023 | Article

ESMO 2023: which peers and resources did eHCPs trust?

While a plethora of HCPs posted online, not all posts had the same reach...

By Alexandra Maria Chatziioannidou

11.08.2023 | Article

Online conversations suggest US HCPs are not yet convinced about Daiichi Sankyo’s Vanflyta

What eHCPs think of the FDA approved the use of Vanflyta, as an FTL3 inhibitor

By Hannah Ghinn

View all articles >